Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Antivirals Market Size Shifted, And What Is the Outlook Through 2034?
The dimension of the antivirals market has notably expanded in the last few years. It’s projected to escalate from $106.64 billion in 2024 to $114.4 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors can explain the growth in this historic period – factors like the prevalence of viral diseases, concerns about public health, expiring patents, and government actions.
In the forthcoming years, the antivirals market size is projected to experience robust growth. It is anticipated to reach a value of $151.54 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 7.3%. This expansion during the forecast period can be linked to the advent of novel viral threats and worldwide health initiatives. Technological advancements, the emergence of telemedicine and digital health, as well as personalized medicine are the key trends set to dominate the forecast period.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Antivirals Market?
The growth of the antiviral market is expected to be driven by the rising occurrence of influenza. Often referred to as flu, influenza is an extremely transmittable viral respiratory infection instigated by influenza viruses affecting the nose, throat, and lungs. Antivirals, which are created to disrupt the proliferation and diffusion of these viruses within the human body, offer a treatment option for influenza. For example, the US health agency, Centers for Disease Control and Prevention, reported in October 2022, that there were 9 million cases of flu illnesses, 4 million medical consultations related to the flu, 100,000 hospitalizations due to flu, and 5,000 flu fatalities during the 2021-2022 season. As a result, the escalating incidence of influenza is fueling the expansion of the antiviral market.
Which Key Market Segments Comprise the Antivirals Market and Drive Its Revenue Growth?
The antivirals market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications
Subsegments:
1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)
2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=2437&type=smp
Which Areas Are Leading Regions in the Antivirals Market Expansion Across the Globe?
North America was the largest region in the anti-viral drug therapy market in 2024. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Strategic Trends Steering theAntivirals Market Direction?
Leading firms in the antiviral market are prioritizing the development of innovative therapies like oral antiviral interventions to enhance patient adherence, increase accessibility, lower healthcare expenses, and deliver more efficient and user-friendly solutions for managing viral infections. Oral antiviral therapy involves the use of medication consumed orally to combat viral infections. These therapeutic modalities function by obstructing the capacity of viruses to multiply or disseminate within the organism, thereby curtailing the severity and duration of the infection. For example, Pfizer, a US pharmaceutical company, announced in May 2023 its approval for Paxlovid, heralding it as the inaugural oral antiviral remedy for COVID-19 in adults, sanctioned by the Food and Drug Administration, a US government agency. This endorsement carries immense importance as it offers a novel management strategy for COVID-19, particularly as the pandemic appears to be shifting to an endemic stage. Paxlovid is expressly meant for adults with mild-to-moderate COVID-19 who have a high probability of escalating to severe disease, encompassing hospitalization or mortality.
View the full report here:
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
How Is the Antivirals Market Conceptually Defined?
Antivirals are medications designed to treat viral infections by inhibiting the replication of viruses within the host’s cells. Unlike antibiotics, which target bacteria, antivirals are specifically used to combat viruses such as the flu, HIV, or hepatitis. They work by interfering with various stages of a virus’s lifecycle, helping to reduce the severity and duration of an infection.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2437
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model